{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:27:26Z","timestamp":1787624846862,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL168611"],"award-info":[{"award-number":["R01 HL168611"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL149893"],"award-info":[{"award-number":["R01 HL149893"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL095685"],"award-info":[{"award-number":["R01 HL095685"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SRSF2 mutations are found in association with JAK2V617F in myeloproliferative neoplasms (MPN), most frequently in myelofibrosis (MF). However, the contribution of SRSF2 mutation in JAK2V617F-driven MPN remains elusive. To investigate the consequences of SRSF2<jats:sup>P95H<\/jats:sup> and JAK2<jats:sup>V617F<\/jats:sup> mutations in MPN, we generated Cre-inducible Srsf2<jats:sup>P95H\/+<\/jats:sup>Jak2<jats:sup>V617F\/+<\/jats:sup> knock-in mice. We show that co-expression of Srsf2<jats:sup>P95H<\/jats:sup> mutant reduced red blood cell, neutrophil, and platelet counts, attenuated splenomegaly but did not induce bone marrow fibrosis in Jak2<jats:sup>V617F\/+<\/jats:sup> mice. Furthermore, co-expression of Srsf2<jats:sup>P95H<\/jats:sup> diminished the competitiveness of Jak2<jats:sup>V617F<\/jats:sup> mutant hematopoietic stem\/progenitor cells. We found that Srsf2<jats:sup>P95H<\/jats:sup> mutant reduced the TGF-\u03b2 levels but increased the expression of S100A8 and S100A9 in Jak2<jats:sup>V617F\/+<\/jats:sup> mice. Furthermore, enforced expression of S100A9 in Jak2<jats:sup>V617F\/+<\/jats:sup> mice bone marrow significantly reduced the red blood cell, hemoglobin, and hematocrit levels. Overall, these data suggest that concurrent expression of Srsf2<jats:sup>P95H<\/jats:sup> and Jak2<jats:sup>V617F<\/jats:sup> mutants reduces erythropoiesis but does not promote the development of bone marrow fibrosis in mice.<\/jats:p>","DOI":"10.1038\/s41408-023-00947-y","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T08:01:58Z","timestamp":1701072118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm"],"prefix":"10.1038","volume":"13","author":[{"given":"Yue","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8383-4876","authenticated-orcid":false,"given":"Salar","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9903-6959","authenticated-orcid":false,"given":"Mohammad A.","family":"Sayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0368-2858","authenticated-orcid":false,"given":"Avik","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7530-4784","authenticated-orcid":false,"given":"Golam","family":"Mohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"947_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667\u201379.","journal-title":"Blood"},{"key":"947_CR2","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","volume":"115","author":"H Akada","year":"2010","unstructured":"Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115:3589\u201397.","journal-title":"Blood"},{"key":"947_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, AI-Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17:584\u201396.","journal-title":"Cancer Cell"},{"key":"947_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","volume":"116","author":"C Marty","year":"2010","unstructured":"Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010;116:783\u20137.","journal-title":"Blood"},{"key":"947_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:861\u20131869.","journal-title":"Leukemia"},{"key":"947_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021;96:145\u201362.","journal-title":"Am J Hematol"},{"key":"947_CR7","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1182\/blood-2015-11-679431","volume":"127","author":"Y Yang","year":"2016","unstructured":"Yang Y, Akada H, Nath D, Hutchison RE, Mohi G. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood. 2016;127:3410\u201323.","journal-title":"Blood"},{"key":"947_CR8","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1084\/jem.20151121","volume":"213","author":"G Sashida","year":"2016","unstructured":"Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, et al. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med. 2016;213:1459\u201377.","journal-title":"J Exp Med"},{"key":"947_CR9","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1084\/jem.20151136","volume":"213","author":"T Shimizu","year":"2016","unstructured":"Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, et al. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016;213:1479\u201396.","journal-title":"J Exp Med"},{"key":"947_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41375-018-0347-y","volume":"33","author":"Y Guo","year":"2019","unstructured":"Guo Y, Zhou Y, Yamatomo S, Yang H, Zhang P, Chen S, et al. ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Leukemia. 2019;33:1287\u201391.","journal-title":"Leukemia"},{"key":"947_CR11","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1182\/blood-2018-04-846220","volume":"132","author":"S Jacquelin","year":"2018","unstructured":"Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, et al. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood. 2018;132:2707\u201321.","journal-title":"Blood"},{"key":"947_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/blood-2014-04-567024","volume":"125","author":"E Chen","year":"2015","unstructured":"Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015;125:327\u201335.","journal-title":"Blood"},{"key":"947_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1097-2765(00)80076-3","volume":"1","author":"BR Graveley","year":"1998","unstructured":"Graveley BR, Maniatis T. Arginine\/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol Cell. 1998;1:765\u201371.","journal-title":"Mol Cell"},{"key":"947_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64\u201369.","journal-title":"Nature"},{"key":"947_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","volume":"33","author":"S Ogawa","year":"2019","unstructured":"Ogawa S. Genetics of MDS. Blood. 2019;33:1049\u201359.","journal-title":"Blood"},{"key":"947_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27:617\u201330.","journal-title":"Cancer Cell"},{"key":"947_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1182\/blood-2017-01-762393","volume":"13","author":"A Kon","year":"2018","unstructured":"Kon A, Yamazaki S, Nannya Y, Kataoka K, Ota Y, Nakagawa MM, et al. Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood. 2018;13:621\u201335.","journal-title":"Blood"},{"key":"947_CR18","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1126\/science.7660125","volume":"269","author":"R K\u00fchn","year":"1995","unstructured":"K\u00fchn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269:1427\u20139.","journal-title":"Science"},{"key":"947_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","volume":"290","author":"J Prchal","year":"1974","unstructured":"Prchal J, Axelrad AA. Bone-marrow responses in polycythemia vera. N Engl J Med. 1974;290:1382.","journal-title":"N Engl J Med"},{"key":"947_CR20","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2012-06-439661","volume":"121","author":"M Zingariello","year":"2013","unstructured":"Zingariello M, Martelli F, Ciaffoni F, Masiello F, Ghinassi B, D\u2019Amore E, et al. Characterization of the TGF-\u03b21 signaling abnormalities in the Gata1low mouse model of myelofibrosis. Blood. 2013;121:3345\u201363.","journal-title":"Blood"},{"key":"947_CR21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm.4097","volume":"22","author":"SC Lee","year":"2016","unstructured":"Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016;22:672\u20138.","journal-title":"Nat Med"},{"key":"947_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nm.4047","volume":"22","author":"RK Schneider","year":"2016","unstructured":"Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016;22:288\u201397.","journal-title":"Nat Med."},{"key":"947_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","volume":"133","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133:1039\u201348.","journal-title":"Blood"},{"key":"947_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1182\/blood-2018-04-845602","volume":"132","author":"MF Smeets","year":"2018","unstructured":"Smeets MF, Tan SY, Xu JJ, Anande G, Unnikrishnan A, Chalk AM, et al. Srsf2P95H initiates myeloid bias and myelodysplastic\/myeloproliferative syndrome from hemopoietic stem cells. Blood. 2018;132:608\u201321.","journal-title":"Blood"},{"key":"947_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","volume":"120","author":"A Mullally","year":"2012","unstructured":"Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012;120:166\u201372.","journal-title":"Blood"},{"key":"947_CR26","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1084\/jem.20131371","volume":"211","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Takizawa H, Kubovcakova L, Guo G, Hao-Shen H, Dirnhofer S, et al. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J Exp Med. 2014;211:2213\u201330.","journal-title":"J Exp Med"},{"key":"947_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020;587:555\u201366.","journal-title":"Nature"},{"key":"947_CR28","doi-asserted-by":"publisher","first-page":"e20190103","DOI":"10.1084\/jem.20190103","volume":"217","author":"NG Frangogiannis","year":"2020","unstructured":"Frangogiannis NG. Transforming growth factor-\u03b2 in tissue fibrosis. J Exp Med. 2020;217:e20190103.","journal-title":"J Exp Med"},{"key":"947_CR29","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","volume":"23","author":"A Tefferi","year":"2005","unstructured":"Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23:8520\u201330.","journal-title":"J Clin Oncol"},{"key":"947_CR30","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","volume":"100","author":"H Chagraoui","year":"2002","unstructured":"Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495\u2013503.","journal-title":"Blood"},{"key":"947_CR31","doi-asserted-by":"publisher","first-page":"e90932","DOI":"10.1172\/jci.insight.90932","volume":"2","author":"L Yue","year":"2017","unstructured":"Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, et al. Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017;2:e90932.","journal-title":"JCI Insight"},{"key":"947_CR32","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41375-021-01464-2","volume":"36","author":"A Dutta","year":"2022","unstructured":"Dutta A, Nath D, Yang Y, Le BT, Rahman MF, Faughnan P, et al. Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models. Leukemia. 2022;36:746\u201359.","journal-title":"Leukemia"},{"key":"947_CR33","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1172\/JCI67580","volume":"123","author":"X Chen","year":"2013","unstructured":"Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Investig. 2013;123:4595\u2013611.","journal-title":"J Clin Investig"},{"key":"947_CR34","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41375-023-01878-0","volume":"37","author":"C Willekens","year":"2023","unstructured":"Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, et al. SRSF2-P95H decreases JAK\/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia. 2023;37:1287\u201397.","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00947-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00947-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00947-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:03:29Z","timestamp":1701129809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00947-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00947-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"6 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GM received research funding from Sumitomo Pharma Oncology and Erasca Inc. in projects outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}